Adults living with HIV now have an option to start injectable regimen without the need for an oral lead-in period first TITUSVILLE, N.J., March 24, 2022 - The Janssen. | March 24, 2022
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly with injections For media and investors
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022Data reinforce ViiV Healthcare’s leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention London, 7 February 2022 – ViiV Healthca.
Data reinforce ViiV Healthcare's leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention ViiV Healthcare, the global specialist HIV company majority-owned
For media and investors only Issued: London UK Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living. | February 1, 2022